Introduction
The human dopamine transporter (DAT) gene (SLC6A3) encodes the member of the neurotransmitter transporter gene family 1 that reaccumulates the neurotransmitter dopamine into presynaptic terminals. This transporter is the primary regulator of the time course and synaptic concentration of released dopamine, which is a key neurotransmitter for regulation of mood and movement.
Several lines of evidence suggest that variants of the dopamine transporter gene could play important roles in a number of neuropsychiatric disorders. Cocaine and other psychostimulants block DAT function; DAT has been postulated to be a key site for psychostimulant reward. 2 The ability of virtually all abused substances to enhance dopamine release makes DAT a candidate contributor to vulnerability to many classes of abused substances. Other disorders with documented dopaminergic involvement in pathogenesis and/or treatment include Parkinson's disease, schizophrenia, attention deficit hyperactivity disorder (ADHD) and Tourette's syndrome. [3] [4] [5] Dopamine trans-porter inhibitors, including psychostimulants and bupropion, are currently among the most efficacious treatments in ADHD. In vitro studies of DAT site-directed mutants document that many single amino acid DAT substitutions selectively alter aspects of DAT function likely to be important for its selective properties. 6 Transgenic mice with altered DAT expression, both knockouts and transgenic over-expressors, are differentially vulnerable to Parkinsonism-inducing neurotoxins, 7 display different locomotor habituation patterns, and reveal differing locomotor responses to psychostimulants. 8, 9 DAT gene sequence variants are thus attractive candidates for contributing to several human disorders with significant morbidity and mortality.
Previously-described DAT sequence variants have been used to analyze the potential genetic contribution of this gene to several of the disorders mentioned above. An allelic variant marked by a 10-copy variable number tandem repeat (VNTR) marker at the 3Ј end of the DAT gene locus has been associated with ADHD in three independent family-based controlled studies, [10] [11] [12] [13] athough it could not be found in one association study.
14 The 9-copy repeat has been found more frequently in unrelated cocaine abusers who report paranoid ideation with cocaine use. 15 Suggestive linkage has been reported between DAT and bipolar disorder. 16 More recently, alcohol withdrawal symptoms were found to be more pronounced in chronically intoxicated patients who had the 9-copy DAT allele. 17 Association and/or linkage studies of VNTR marker frequencies have also been reported in drug abuse, 18 alcohol abuse, 19, 20 [24] [25] [26] These marker studies, however, do not provide maximal sensitivity for detecting polymorphisms across the entire DAT locus. More adequate evaluation of the possibility that DAT gene variants could contribute differences in protein coding requires additional DAT genomic sequence information as well as information about individual variants in the additional sequences.
Initial work in elucidating human DAT genomic sequences revealed that the first 12 human DAT gene exons were distributed over at least 50 kb of genomic DNA located at chromosome 5p15.3. 27 Alignment of these partial genomic clones with human DAT cDNA sequences indicated the presence of additional 3Ј exons, including an exon containing the VNTR polymorphism that lies in the DAT cDNAs 3Ј untranslated region. We now report complete elucidation of the primary sequence of the entire DAT gene and more than 8 kb of 5Ј-flanking sequence. Variants in these sequences have been identified by single-stranded conformational polymorphism and direct sequencing of DNA amplified from each DAT genomic exon and from several introns. We have examined both disease populations and individuals free of neuropsychiatric disorders.
Materials and methods

DAT exons 13, 14 and 15. Isolation and complete sequence
Genomic clones were isolated by standard hybridization screening of phage libraries (Clontech, Palo Alto, CA, USA) using probes from the 3Ј-end of the hDAT cDNA. 28 Phage DNA was isolated from plate lysates using a phage DNA isolation kit (Stratagene, La Jolla, CA, USA) and subcloned into pBluescript II for subsequent analysis. Regions of the gene that were not found in these plasmids were cloned by long PCR using the LA PCR kit (TaKaRa, Panvera, Madison, WI, USA). Clones from the 5Ј-flank through exon 12, described in Donovan et al, 27 have now been sequenced in their entirety. Automated sequencing of introns (single stranded) and exons (double stranded) was performed using ABI sequencers (Applied Biosystems, Foster City, CA, USA) at the Johns Hopkins Core Facility.
Research volunteers
Individuals volunteered for inclusion in study groups under appropriate informed consent provisions. Racial and ethnic classifications were determined by selfreport. Table 1 provides a brief summary of the volunteers from the three institutions that participated in this work. No research volunteer from the National Institute of Drug Abuse Intramural Research Program had any prominent current psychiatric symptomatology. None had a Symptomatology Check List (SCL-90) t score more than 70, and high values in any single category excluded potential subjects from participation. Control individuals from Toronto were free from psychiatric disorders as determined by the Pharmaco Dependence Health Questionnaire. 29 A total of 128 Caucasian controls of western and northern European descent were recruited in a study of drug abuse at the National Institute on Drug Abuse Intramural Research Program. Additional control volunteers, free from diagnoses of psychiatric disorders, were recruited from an adjacent hemodialysis unit and a public health facility studying HIV infection in Baltimore. For exon sequencing to detect new mutations, individuals were selected on the basis of DAT VNTR allele status (described below under direct sequence screening for variants) and included some AfricanAmericans who attended a Baltimore area sickle-cell anemia clinic. 30 The families of 47 child or adolescent probands with DSM-III-R ADHD 31 (Am. Psych. Assoc.) diagnoses made at the University of Chicago Hyperactivity, Attention, and Learning Problems (HALP) clinic between April 1993 and October 1994 formed the ADHD sample tested previously for linkage disequilibrium with the 3Ј-DAT VNTR. 10 Fifteen of these individuals were chosen based on their having received the 3Ј-VNTR 10-copy allele from at least one heterozygous parent. These individuals were screened for polymorphisms in the DAT gene by both SSCP and bidirectional sequencing.
Unrelated Caucasian individuals of non-Hispanic, northern or western European descent were sampled at the Centre for Addiction and Mental Health (CAMH), Toronto, Canada. Sixty-four individuals meeting DSM-III-R diagnoses of alcohol dependence were compared to 64 matched controls free from alcohol dependence selected from the CAMH.
Tourette's clinic patients consisted of consecutive, unrelated individuals of non-Hispanic, northern or western European descent. There were 109 probands treated at the TS clinic of the City of Hope National Medical Center (COH). Eighty-two percent met DSM diagnosis of TS and 18% had other chronic motor or vocal tic disorders. Thirty-five of these volunteers responded positively to DIS/DSM-III-R questions about ADHD and 22 to questions about obsessive compulsive disorder. These results were compared to those of a control group consisting of 67 individuals from the CAMH.
All comparisons of unrelated individuals by allele status and disorder phenotype were made by 2 analyses, with the exception of the ADHD families. ADHD families, who were analyzed by the Transmission Disequilibrium Test (TDT) 32 were not separated by race since the TDT provides an internal control for racial stratification, all other subjects were of northern and western European descent.
Research volunteer DNA
Blood samples were obtained by venipuncture following informed consent. Genomic DNA was isolated by phenol extraction and ethanol precipitation of DNA from most blood samples as previously described. 30 DNA samples from the University of Chicago were isolated without phenol, as previously described. 10 
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DAT VNTR and TaqA polymorphism detection by PCR and PCR-RFLP
A previously described polymorphism initially detected by Southern analyses of TaqI digests 28 was detected by PCR amplification using the oligonucleotide primers HDATTaqAFor (5Ј-CCGTGCCAGCTCC TGCTG-3Ј) and HDATTaqARev (5Ј-GACCTCAGT GGTGTCTGTTGATACGG-3Ј) for 35 cycles of 98°C for 10 s, 67°C for 60 s, 72°C for 60 s followed by TaqI digestion and polyacrylamide gel electrophoresis. The expected band sizes are 623 bp for the A1 allele, and 423 plus 200 bp for the A2 allele.
The exon 15 VNTR was amplified using the oligonucleotide primers T3-5Long (5Ј-TGTGGTGTA GGGAACGGCCTGAG-3Ј) and T7-3aLong (5Ј-CTTCCTGGAGGTCACGGCTCAAGG-3Ј) under conditions previously described. 33 
Intron polymorphisms
Alleles of an intron 8 VNTR were detected by PCR amplification of 40 ng of genomic DNA from 21 Caucasian and 24 African-American control individuals using the primers Int8RepFor (5Ј-GCACAAAT GAGTGTTCGTGCATGTG-3Ј) and Int8RepRev (5Ј-AGCAGGAGGGGCTTCCAGGC-3) and 35 cycles of 98°C for 10 s and 67°C for 60 s, which was initiated by the addition of Taq polymerase in the first cycle at 82°C (Hot Start). Fragment sizes are 260 bp and 290 bp for the five-and six-copy alleles respectively, determined using 5% polyacrylamide gel electrophoresis.
SSCP analyses
Sequences of the oligonucleotides used as PCR primers to amplify each DAT exon and intron 14 are listed in Table 2 . PCR reactions used 200 ng genomic DNA, 50 pmol of each oligonucleotide primer, 300 M dNTP, 1.5 mM MgCl 2 , 0.5 U Taq DNA polymerase (Life Technologies, Gaithersburg, MD, USA) and 40 cycles of 95°C for 30 s, 60-68°C for 40 s, and 72°C for 40 s in a Perkin Elmer GeneAmp 9600. For SSCP analyses conducted at the University of Toronto on samples from the COH and CAMH, PCR products were diluted 1:4 in SSCP loading buffer (0.04% SDS, 16 mM EDTA, 57% formamide, 0.03% bromophenol blue and 0.03% xylene cyanol) heated at 95°C for 5 min, and rapidly cooled to 0°C for 5 min before electrophoresis using Novex Xcell II minicells. 34, 35 Five sets of condition variants were used: (a) 400 volts, 10 mA at 2.5 W; (b) 100 V-h; (c) 6°C in loading buffer without glycerol; (d) 15°C in loading buffer containing glycerol; and (e) 100 volts for 18 h at 4°C on 4-20% TBE gradient gels. DNA was visualized by silver staining. Samples in which variants were detected by SSCP were cloned (pBluescript), and multiple isolates were sequenced manually [USB Sequenase PCR Product Sequencing (Cleveland, OH, USA), or Pharmacia-Biotech T7 sequencing (Uppsala, Sweden)] to identify the nucleotides responsible for the variations.
SSCP electrophoresis at the University of Chicago was performed using Phast System 20% polyacrylamide gels at 6°C without glycerol in the loading buffer, or at 15°C with glycerol. All samples from the University of Chicago were sequenced bidirectionally from PCR products, regardless of whether a variant was detected by SSCP or not. Direct sequencing failed to identify any variants not detected by SSCP screening under at least one set of conditions (see below).
Direct sequence screening for variants
Ten of the individuals from the NIDA samples were selected for direct sequence analysis without preceding SSCP analysis, based on the occurrence of exon 15 VNTR alleles containing at least one copy of the less common 3, 5, 7, 8 or 11 repeat variants. Ten additional individuals were selected based on their expression of the more common 9-or 10-copy variants to maximize the opportunities for finding novel alleles. Fifteen children from the University of Chicago, who had ADHD and evidence of transmission of the 10-copy allele from a heterozygous parent, were directly sequenced from both strands using primers that flanked each of the exons using an ABI 310 sequencer. DAT exons from DNA from NIDA and the University of Chicago, were amplified by PCR using the primers described in Table  2 and sequenced using universal M13 forward or reverse sequences (footnote and Table 2b ), which had been included at the 3Ј and 5Ј ends of the primer sequences. For those exon primers that formed hairpins with an M13 tail, one of the two PCR primers was used for sequencing. Sequences generated have been submitted to GenBank (Accession No. AF119117). 27 and have been included here for a complete description of the gene.
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Results
Gene structure A total of 59747 bp of sequence comprising the complete DAT gene has been determined, including 8.6 kb of 5Ј-flanking sequence (Figure 1a ) (GenBank accession No. AF119117). The sequences substantially supplement the 5622 bp of sequence previously reported, 27 which described the immediate 5Ј flank of the first exon, the first 12 exons, and minimal intron sequence. Exons 13 and 14, which could not be detected in genomic DNA libraries, were cloned by long PCR amplification using primer pairs specific to exons 13 and 14, and 14 and 15, followed by subcloning the PCR products (Figure 1c ). Exon 15 of the DAT gene was identified in genomic clones by hybridization to DAT cDNA sequences. One of these clones, cosmid M77-1, was a generous gift from John Wasmuth and Deanna Church (University of California at Irvine) and also contains the anonymous marker D5S678 approximately 25 kb downstream of DAT exon 15 (data not shown). This independently determined DAT gene structure and sequence also completes the structure recently presented by Kawarai et al. 36 The positions of exon/intron boundaries, shown in Table 3 , are completely conserved with those of the norepinephrine, 37 serotonin, 38 and GABA transporters. 39 Exon 13 encodes a small part of putative transmembrane domain 11 and all of transmembrane domain 12 of the DAT protein. Exon 14 is the smallest of the exons (71 nucleotides). Exon 15 encodes the last seven amino acids of DAT and all 1946 nucleotides of the 3Ј-untranslated region of the mRNA, and thus is as large as all of the other exons combined. The combined size of the exons (4 kb) agrees with the size of mRNA detected by Northern analysis. 27 Sequences in intron 14 proved to be particularly unstable in bacterial vectors. Comparisons of the sequences of an intact intron 14 clone with those of several clones with deletions appeared to indicate that two copies of an Alu repetitive element contributed to this instability. These data add to previously reported observations to form the map of the human DAT gene (Figure 1 ).
Repetitive element in intron 8
Studies of DAT genomic sequences revealed several markers for DAT variants. Intron 8 contained a VNTR polymorphism approximately 2.6 kb 3Ј to exon 8 and 390 bp 5Ј to exon 9. This VNTR consisted of either five or six copies of a 30-bp repetitive element. The 6-copy allele was found in 38% of Caucasian chromosomes, but was found in 79% of chromosomes from AfricanAmericans. An imperfect GT dinucleotide repeat was identified in intron 13, but was not polymorphic in more than 20 individuals studied (data not shown).
Variants in exon sequences
SSCP was used to analyze amplified products of the 15 DAT exons and exon-intron junctions from 109 Caucasian individuals with City of Hope criteria for Tourette's syndrome and 67 Caucasian controls free of psychiatric diagnoses. DNA of exons 1, 3, 4, 5, 10 and 14 from these individuals revealed no evidence for polymorphisms by SSCP. Individuals from the University of Chicago (n = 15) also failed to reveal polymorphisms in these exons by SSCP analysis. Sequencing exon amplification products from unrelated individuals sampled at the NIDA-IRP also failed to identify any variants in exons 1, 3, 4, 5, 10 and 14. These results included data from individuals included in this sample based on their possession of the more uncommon 3, 5, 7, 8 or 11-copy VNTR alleles from exon 15.
Three exons did reveal evidence for common sequence variants. Five additional less common sequence variants were also identified (Table 4) . No common sequence variant altered the DAT protein sequence. Two of the rarer mutations do produce conservative amino acid changes. The exon 15 sequence variant listed in Table 4 resulted from a T substituted for the more common C at base pair 1999, which lies at the beginning of the 3Ј untranslated region of the DAT mRNA and 715 nucleotides 5Ј to the previouslyreported VNTR in exon 15. However, only the first 200 nucleotides of the exon, containing the last 21 nucleotides of coding region, were tested for variants. Other variants might be present in the remainder of the 3Ј untranslated region.
Relationship of polymorphisms to disease
When all of the ADHD subjects (n = 47) from the earlier study of the exon 15 VNTR 10 were considered with the exon 15 VNTR, strong preferential transmission of the 10-copy form was again detected as previously reported using HHRR analyses (TDT 2 = 7.00, 1 df, P = 0.008). Transmission disequilibrium was also detected by the exon 15 nucleotide 1999 polymorphism, (TDT 2 = 4.48, 1 df, P = 0.034), but was weaker than the finding with the VNTR in the same sample ( Figure 2 ). There was no evidence of transmission disequilibrium of either the exon 2 or the exon 9 polymorphisms in individuals with ADHD. Values for the exon 2 TDT 2 was 0.5, 1 df, P = 0.480, and the exon 9 TDT 2 was 0.18, 1 df, P = 0.671. There were no striking differences in the frequencies of any of these single nucleotide sequence variants in any of the populations studied by case-controlled association tests (Figure 3 ), although the low number of rarer mutations identified here provides us with less opportunity to assess their possible impact. The exon 15 nucleotide 1999 allelic variant was present in 26% of 148 unrelated parental chromosomes examined at the University of Chicago and 45% of the chromosomes from unrelated NIDA volunteers. SSCP analysis of the exon 15 single-nucleotide polymorphism showed that it was present at similar frequencies in Caucasian alcoholics (27%), and individuals with Tourette's syndrome (20%). Frequencies in individuals with Tourette's syndrome comorbid with ADHD were 21%, and in Tourette's syndrome with features of obsessive/ compulsive disorder the frequency was 22%.
Discussion
For simple genetic disorders, assessment of the coinheritance of an informative candidate gene locus Molecular Psychiatry marker along with the trait can allow straightforward confirmation or exclusion of the hypothesis that genetic variation at the locus causes the disease with high statistical certainty. 40 Although it would be desirable to approach this degree of certainty for the many common disorders that display complex genetic bases, these disorders often display evidence for genetic heterogeneity, substantial environmental influences and other features that make classical genetic analyses more difficult. Virtually all of the disorders for which DAT is a plausible candidate locus fall into this more complex genetic category. 41 Thus, any relationship between the DAT gene and neuropsychiatric disorders will be likely to be complex even though DAT remains a strong candidate to contribute, along with other genes, to these traits. As Falconer notes, 'Quantitative differences, in so far as they are inherited, (may) depend on genes whose effects are small in relation to the variation arising from other causes.' 42 Understanding of the inheritance of such differences nevertheless may lead to greater understanding of both genetic and non-genetic contributions to these disorders that, collectively, provide substantial morbidity and mortality.
To be able to include or exclude roles for DAT gene variants in dopamine-related disorders with increasing confidence, we need to develop more detailed knowledge of the locus, and the genetic variability that the The data are presented for the more common allele at each site, expressed as % of controls for each group except in the case of the exon 2 polymorphism, for which DNA from controls without alcohol dependence was not available. No differences were statistically significant (P values ranged from 0.16 to 0.93). *For exon 2, the C/T polymorphism detected is at nucleotide 272. locus displays in different populations. This information will allow more and more of the locus to be excluded as making significant contribution to these disorders with increasing confidence. The exact sites responsible for positive associations can also be established with increasing precision. Because association and affected-sib-pair model studies have provisionally implicated DAT gene alleles in several such disorders, closer examination of this gene's sequences sufficient to define human variation at this locus and to allow near 'exclusion' of variation at this gene in these disorders is of particular importance. Since the DAT marker tentatively implicated in several disorders lies in the gene's 3Ј region, improving definition of the last three DAT exons and close examination of each protein-coding sequence in normal and disease populations is an important step in this process. Exclusion of allelic variations in unselected population samples or in disease sub-populations requires examination of relatively large numbers of individuals, made practical with use of SSCP or related methods such as denaturing gradient gel electrophoresis (DGGE). 43 Examination with direct sequencing also improves our confidence in the sensitivity with which we can detect any common allelic variations or mutations.
Our analyses have defined the structures of each of the DAT gene's exons, and have identified three common silent third-position polymorphisms that allow improved sensitivity for association studies of neuropsychiatric disorders.
Although the frequency of the exon 15 polymorphism in the 20 Canadian individuals with selfreported African ancestry described here appears higher than that in other control and disease populations, previous work in substantially larger African American samples failed to reveal significant differences in the frequencies of these markers. We thus cannot now conclude that dramatic racial differences exist for this marker. The current results should be extended to larger African Canadian samples. Sub-Saharan African populations can display substantial genetic diversity, 44 highlighting the need for larger studies in African Canadian and African American populations.
No individual in any of the disease sub-populations selected displayed any polymorphism that was totally absent in control disease-free individuals (Figure 3) . The higher frequencies of the more common exon 2 and exon 9 polymorphisms allow us to relatively confidently exclude any robust association between variants at these portions of the DAT gene locus and the disorders for which significant numbers of individuals were sampled. No contribution to either Tourette's syndrome spectrum or alcohol dependence is supported from this work. These marker frequencies are also similar in polysubstance abuser and control clinical populations. 18 Single studies have also suggested that 9-copy VNTR frequencies are elevated in the cocaine abuser subpopulation that experience paranoia with cocaine use, 15 alcoholics who are habitually violent 45 and alcoholics who display more pronounced alcohol withdrawal. 17 In the ADHD samples in which the exon 15 VNTR association was initially described, 10, 46 the single nucleotide 1999 exon 15 C allelic variant was also preferentially transmitted to children with ADHD. There was no evidence of preferential transmission of either DAT exon 2 or 9 markers to the ADHD children, however.
This comprehensive evaluation of 2053 bp of DAT gene exons and about 700 bp of flanking sequence has identified 16 sequence variants, 12 in exon sequences. Only two of the rarer variants result in amino acid substitution, none of the others change the DAT protein coding sequence. This substantial conservation is consistent with the idea that normal DAT function is evolutionarily important. These data are also consistent with the conservation of this transporter gene's structure with those of other transporter gene family members, even those located on other chromosomes. [37] [38] [39] Such data, as well as other work mentioned above, provide increasing interest in the possibility that level-ofexpression variation, rather than protein sequence variants, may provide the common individual differences at the human DAT gene locus. Mutations in promoter/enhancer regions of this gene could even provide a significant impact on the dopaminergic brain function and dysfunction.
